V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320004262 | 320002626 | 1.75 | 79.4 | null | 2016-11-05 | 2016-11-13 | TIP | N | N | 320025079 | CETUXIMAB + RT |
| 320004263 | 320002627 | 1.79 | 70 | Adjuvant (A) | 2016-01-15 | 2016-01-15 | BORTEZOMIB + THALIDOMIDE | 2 | N | 320025110 | CISPLATIN + GEMCITABINE |
| 320004264 | 320002627 | 1.78 | 90.3 | Palliative (P) | 2016-05-12 | 2016-05-12 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320025110 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320004265 | 320002628 | 1.52 | 64.8 | Curative (C) | 2015-04-26 | 2015-05-24 | DOXORUBICIN | N | Y | 320025336 | NOT MATCHED |
| 320004266 | 320002629 | 1.63 | null | Palliative (P) | 2015-08-29 | 2015-08-31 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 320002605 | FLUOROURACIL + MITOMYCIN + RT |
| 320004267 | 320002629 | 1.78 | 68 | Disease modification (D) | null | 2017-09-26 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320002605 | ETOPOSIDE + IFOSFAMIDE |
| 320004268 | 320002630 | 0 | 71 | Curative (C) | 2017-04-20 | 2017-04-28 | BENDAMUSTINE + RITUXIMAB | N | N | 320003573 | CISPLATIN + GEMCITABINE |
| 320004269 | 320002630 | 1.5 | 56.2 | Palliative (P) | 2015-11-24 | 2015-11-29 | Temozolomide 150mg/m2 | N | N | 320003573 | CARBOPLATIN + ETOPOSIDE |
| 320004270 | 320002630 | null | null | Adjuvant (A) | 2018-03-28 | 2018-03-28 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320003573 | CAV |
| 320004271 | 320002631 | null | 50.8 | Palliative (P) | 2017-11-11 | 2017-11-14 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | N | null | 320005218 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 320004272 | 320002632 | 1.59 | 56.1 | Adjuvant (A) | 2017-09-23 | 2017-09-29 | CETUXIMAB + RT | 02 | N | 320005537 | PEMBROLIZUMAB |
| 320004273 | 320002633 | null | null | Adjuvant (A) | 2018-10-29 | 2018-11-02 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 320006433 | CISPLATIN + PEMETREXED |
| 320004274 | 320002634 | 1.58 | 48 | Palliative (P) | 2019-01-14 | 2019-01-26 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320006654 | CAV |
| 320004275 | 320002635 | 1.67 | 94.7 | Curative (C) | 2017-01-21 | 2017-02-09 | PEMBROLIZUMAB | N | N | 320007575 | PEMBROLIZUMAB |
| 320004276 | 320002636 | 1.67 | 89 | Palliative (P) | 2017-08-18 | 2017-08-25 | Vinflunine | N | N | 320008094 | BEVACIZUMAB |
| 320004277 | 320002636 | 1.8 | 92.7 | Palliative (P) | 2017-02-05 | 2017-02-16 | Cisplatin+Gemcitabine (Days 1&8&15) | N | N | 320008094 | CISPLATIN + GEMCITABINE |
| 320004278 | 320002636 | 1.55 | 0 | Adjuvant (A) | 2017-12-01 | 2017-12-14 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320008094 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320004279 | 320002637 | 1.64 | 64.7 | Palliative (P) | null | 2018-10-16 | BEVACIZUMAB + CARBO | N | N | 320008581 | CETUXIMAB + RT |
| 320004280 | 320002638 | 1.55 | 74.7 | Palliative (P) | 2016-07-03 | 2016-07-17 | CARBOPLATIN + RT | N | N | 320009033 | EOX |
| 320004281 | 320002638 | 1.72 | 70.8 | Not known (9) | null | 2018-06-01 | DOCETAXEL + Prednisolone | N | N | 320009033 | CISPLATIN + GEMCITABINE |
| 320004282 | 320002638 | 1.68 | 61 | Palliative (P) | 2014-04-16 | 2014-04-17 | CVP R | 2 | N | 320009033 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 320004283 | 320002639 | 1.66 | 70.6 | Palliative (P) | 2018-10-08 | 2018-10-26 | STS Rhabdo RMS 2005 | 2 | N | 320009862 | PEMBROLIZUMAB |
| 320004284 | 320002640 | 1.66 | 68 | Curative (C) | 2016-09-10 | 2016-09-20 | Cisplatin + Etoposide (3 day) | N | N | 320009872 | CARBOPLATIN + RT |
| 320004285 | 320002640 | 1.64 | 85.3 | Adjuvant (A) | null | 2016-01-17 | Temozolomide + RT | null | null | 320009872 | CETUXIMAB + RT |
| 320004286 | 320002641 | 1.83 | 93.8 | Palliative (P) | 2019-01-16 | 2019-02-04 | Vemurafenib | N | N | 320010225 | NOT MATCHED |
| 320004287 | 320002641 | 0 | 71.2 | Palliative (P) | 2018-01-13 | 2018-01-28 | PCV | N | N | 320010225 | CVD |
| 320004288 | 320002642 | 1.63 | 76.8 | Palliative (P) | 2017-02-25 | 2017-03-13 | Cisplatin + Etoposide po&iv 3 day | Y | N | 320010959 | CISPLATIN + GEMCITABINE |
| 320004289 | 320002642 | null | null | Palliative (P) | 2018-06-30 | 2018-07-04 | Trial Unspecified | N | N | 320010959 | CARBOPLATIN + LIPOSOMAL DOX |
| 320004290 | 320002643 | 1.62 | 61.3 | Curative (C) | 2015-10-09 | 2015-10-09 | CISPLATIN + GEMCITABINE | 02 | Y | 320011851 | EC + DOCETAXEL |
| 320004291 | 320002644 | 1.71 | 51.9 | Neo-adjuvant (N) | 2014-12-26 | 2014-12-27 | Docetaxel | N | N | 320011983 | ENZALUTAMIDE |
| 320004292 | 320002645 | null | 62.6 | Adjuvant (A) | 2017-10-23 | 2017-11-04 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320012126 | NOT MATCHED |
| 320004293 | 320002646 | 1.67 | null | Palliative (P) | 2018-04-24 | 2018-05-05 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320012558 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004294 | 320002646 | 1.66 | 38.1 | Neo-adjuvant (N) | 2019-03-17 | 2019-03-19 | Bevacizumab+Carbo+Pacliaxel | N | N | 320012558 | CISPLATIN + GEMCITABINE |
| 320004295 | 320006412 | 1.78 | 65 | Palliative (P) | 2015-03-11 | 2015-03-25 | Trial Unspecified | N | N | 320014611 | CAPE + CARBOPLATIN + CETUXIMAB |
| 320004296 | 320002647 | 1.55 | 67.9 | Palliative (P) | 2017-06-05 | 2017-06-12 | Capecitabine + Cisplatin | N | N | 320015416 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320004297 | 320005181 | 1.88 | 81 | Neo-adjuvant (N) | null | 2018-08-07 | CARBOPLATIN + RT | N | N | 320015967 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004298 | 320002648 | 1.64 | 82.3 | Neo-adjuvant (N) | 2014-03-27 | 2014-03-27 | TIP | 2 | N | 320016611 | CARBOPLATIN + VINCRISTINE |
| 320004299 | 320002649 | 1.52 | null | Curative (C) | null | 2017-09-10 | MITOMYCIN | null | null | 320016712 | CISPLATIN + ETOPOSIDE |
| 320004300 | 320002649 | 0 | 77.3 | Curative (C) | 2014-12-11 | 2014-12-11 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 2 | Y | 320016712 | CARBO + FLUOROURACIL |
| 320004301 | 320002650 | 1.8 | 79.4 | Adjuvant (A) | 2018-01-01 | 2018-01-01 | BCG Intravesical | N | N | 320017744 | PEMBROLIZUMAB |
| 320004302 | 320002650 | 1.65 | 57 | Palliative (P) | 2018-09-14 | 2018-09-15 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320017744 | CARBO + FLUOROURACIL |
| 320004303 | 320002650 | null | null | Adjuvant (A) | 2018-09-10 | 2018-09-10 | Cisplatin + Gemcitabine (D 1 & 8) | Y | null | 320017744 | CISPLATIN + VINORELBINE + RT |
| 320004304 | 320002650 | 1.77 | 88.5 | Curative (C) | 2014-09-09 | 2014-09-13 | Trial Unspecified | 2 | Y | 320017744 | BCG |
| 320004305 | 320002651 | null | 69.8 | Palliative (P) | 2017-11-06 | 2017-11-21 | CETUXIMAB | N | N | 320019410 | ENZALUTAMIDE |
| 320004306 | 320002652 | 1.7 | 70.7 | Palliative (P) | 2016-02-01 | 2016-02-23 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 320021242 | IPILIMUMAB + NIVOLUMAB |
| 320004307 | 320002653 | 1.79 | 79.9 | Adjuvant (A) | 2016-07-23 | 2016-08-13 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320021269 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004308 | 320002654 | 1.68 | 72.3 | Palliative (P) | 2017-09-10 | 2017-09-15 | Capecitabine (14 days)+Carboplatin | N | N | 320021340 | TRIAL |
| 320004309 | 320005184 | 1.8 | 0 | Neo-adjuvant (N) | 2017-06-26 | 2017-07-04 | Cisplatin+Gemcitabine (Days 1&8&15) | 2 | Y | 320021501 | CETUXIMAB + RT |
| 320004310 | 320002655 | 1.9 | 78 | Curative (C) | 2016-12-09 | 2016-12-09 | Trial Unspecified | Y | Y | 320021807 | FLUOROURACIL + MITOMYCIN |
| 320004311 | 320002656 | 1.6 | 50.8 | Palliative (P) | 2016-06-24 | 2016-06-24 | PEMBROLIZUMAB | 02 | N | 320021917 | IPILIMUMAB |